UK MHRA Approved Novavax COVID-19 Vaccine for 12 to 17 years old
The Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom has approved Nuvaxovid, the COVID-19 vaccine developed by Novavax, for 12 to 17 year old children. This approval follows a review of the safety, effectiveness, and quality of the COVID-19 vaccine in the particular age group, and the expert advice from the independent […]
Continue Reading